Early diarrhoea under sorafenib as a marker to consider the early migration to second‐line drugs

BACKGROUND: Despite atezolizumab and bevacizumab (A + B) is currently the first‐line treatment for hepatocellular carcinoma (HCC) patients, some patients will not be adequate for this combination. In the setting of sorafenib some adverse events have been proposed as prognostic factors. OBJECTIVE: To...

Descripción completa

Detalles Bibliográficos
Autores principales: Díaz‐González, Álvaro, Sapena, Víctor, Boix, Loreto, Torres, Ferrán, Sanduzzi‐Zamparelli, Marco, Da Fonseca, Leonardo G., LLarch, Neus, Iserte, Gemma, Guedes, Cassia, Muñoz‐Martínez, Sergio, Darnell, Anna, Belmonte, Ernest, Rimola, Jordi, Forner, Alejandro, Ayuso, Carmen, Bruix, Jordi, Reig, María
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Hepatobiliary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280813/
https://www.ncbi.nlm.nih.gov/pubmed/34228394
http://dx.doi.org/10.1002/ueg2.12111

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8280813/
https://www.ncbi.nlm.nih.gov/pubmed/34228394
http://dx.doi.org/10.1002/ueg2.12111

Ejemplares similares